The nationwide surveillance on antimicrobial susceptibility of bacterial respiratory pathogens from patients in Japan, was conducted by Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases and Japanese Society for Clinical Microbiology in 2010.
Introduction
In order to investigate comprehensively the antimicrobial susceptibility and resistance of bacterial respiratory pathogens, Japanese Society of Chemotherapy (JSC) established a nationwide surveillance network in 2006. The first survey was conducted in 2006 and we reported the trend of antimicrobial susceptibilities of bacterial species from patients with respiratory tract infections (RTI) [1] . Second and third surveys were continuously conducted in 2007 and in 2008, respectively. After third-year study, this survey was decided to be continued in association with JSC, the Japanese Association for Infectious Diseases and the Japanese Society for Clinical Microbiology. In 2009, the fourth year nationwide surveillance was conducted as the first survey conducted by three societies [2] . Here we report the study of fifth year nationwide surveillance which was the second survey conducted by three societies. These results obtained from this surveillance will be used as a set of controls for those conducted in future by three societies and by other organizations as well.
Materials and methods

Strains and quality control
The bacteria from the patients with RTI were isolated from sputum, specimens collected by trans-tracheal aspiration, or bronchoscopy between April and September in 2010. The subjects in the study were Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Moraxella catarrhalis, Klebsiella pneumoniae and Pseudomonas aeruginosa. Microbiological laboratory test for respiratory pathogens were conducted by standard methods including Gram staining and quantitative culture of various respiratory samples at 34 medical institutions, as listed in Table 1 . The isolated bacteria were identified as species level in each laboratory. The isolates were stored in the freezer and the causative bacteria judged by physicians were collected. When several strains were detected from the same patient, arbitrary 1 strain was selected. The isolates were suspended in Micro-bank tube (Asuka Junyaku Co.Ltd. Tokyo) and transferred to the central laboratory, the Research Center for Anti-infective Drugs of the Kitasato Institute. The electronic uniform data sheets of each patient from whom these strains isolated were also completed at each institution and sent to the Center so that microbiological data obtained were able to be stratified under the settings and profiles of patients and under the diagnoses.
A total of 1001 strains were received at the center and kept at À80 C until the antimicrobial susceptibility testing conducted. Re-identification and cultivation of them gave evaluable 954 strains consisted of 206 S. aureus, 189 S. pneumoniae, 4 S. pyogenes, 182 H. influenzae, 74 M. catarrhalis, 139 K. pneumoniae and 160 P. aeruginosa.
Accuracy of determination for minimum inhibitory concentration (MIC) of antibacterial agents was controlled according to the recommendations of Clinical and Laboratory Standards Institute (CLSI) using the following control strains respectively: S. aureus ATCC29213 and Escherichia coli ATCC35218 for clinical isolates of S. aureus and M. catarrhalis; S. pneumoniae ATCC49619 for S. pneumoniae; H. influenzae ATCC49247 for H. influenzae; E. coli ATCC25922 for K. pneumoniae and P. aeruginosa; and P. aeruginosa ATCC27853 for P. aeruginosa. E. coli ATCC35218 was used as a control strain in case of MIC determination for b-lactam antibiotics combined with b -lactamase inhibitors.
Antibacterial agents
The susceptibilities of the bacterial strains were tested for the following 45 antimicrobial agents: four penicillins such as benzylpenicillin (PCG; Meiji Seika Kaisha Ltd.), oxacillin (MPIPC; Meiji), ampicillin (ABPC; Meiji) and piperacillin (PIPC; Toyama Chemical Co., Ltd.); three penicillins in combination with b-lactamase inhibitors such as clavulanic acid-amoxicillin (CVA/AMPC; Glaxo SmithKline K.K.), sulbactam-ABPC (SBT/ABPC; Pfizer Japan Inc.) and tazobactam-PIPC (TAZ/PIPC; Toyama); four oral cephems such as cefaclor (CCL; Shionogi & Co., Ltd.), cefdinir (CFDN; Astellas Pharma Inc.), cefcapene (CFPN; Shionogi), and cefditoren (CDTR; Meiji); eight parenteral cephems such as cefazolin (CEZ; Astellas), cefoxitin (CFX; Banyu Pharmaceutical Co., Ltd.), cefmetazole (CMZ; Daiichi-Sankyo Co., Ltd.), cefotiam (CTM; Takeda Pharmaceutical Co., Ltd.), ceftazidime (CAZ; Glaxo SmithKline), ceftriaxone (CTRX; Chugai Pharmaceutical Co., Ltd.), cefepime (CFPM; Meiji) and cefozopran (CZOP; Takeda); a monobactam aztreonam (AZT; Eisai Co., Ltd.); five carbapenems such as imipenem (IPM; Banyu), panipenem (PAPM; Daiichi-Sankyo), meropenem (MEPM; Dainippon Sumitomo Pharma Co., Ltd.), biapenem (BIPM; Meiji) and doripenem (DRPM; Shionogi); one penem such as faropenem (FRPM; Astellas); four aminoglycosides such as gentamicin (GM; Shionogi), tobramycin (TOB; J-dolph), amikacin (AMK; Banyu) and arbekacin (ABK; Meiji); three macrolides such as erythromycin (EM; Dainippon Sumitomo), clarithromycin (CAM; Toyama) and azithromycin (AZM; Pfizer); a lincosamide clindamycin (CLDM; Dainippon Sumitomo); a tetracycline minocycline (MINO; Wyeth K.K./Takeda); two glycopeptides such as vancomycin (VCM; Shionogi) and teicoplanin (TEIC; Astellas); seven fluoroquinolones such as ciprofloxacin (CPFX; BayerYakuhin Ltd.), levofloxacin (LVFX; Daiichi-Sankyo), tosufloxacin (TFLX; Toyama), moxifloxacin (MFLX; Shionogi), pazufloxacin (PZFX; Toyama), garenoxacin (GRNX; Astellas), and sitafloxacin (STFX; Daiichi Sankyo) and an oxazolidinone linezolide (LZD; Pfizer). These antimicrobial agents were serially diluted and placed under freeze-dried state in respective wells of microplates. The stability of the antimicrobial agent-containing microplates was guaranteed by the manufacturer (Eiken Kagaku) for 9 months.
Susceptibility testing and MIC determination
Susceptibility testing was performed according to CLSI standards M7-A8 for micro-broth dilution method [3, 4] . In brief, cationadjusted Mueller-Hinton broth (25 mg/L Ca þþ and 12.5 mg/L Mg þþ ;
CAeMH broth) was used to measure MIC against S. aureus, M. catarrhalis, K. pneumoniae and P. aeruginosa. For the determination of the MIC of oxacillin, NaCl was added at 2% to CAeMH broth. For measuring the MICs against S. pneumoniae and H. influenzae, 15 mg/ mL nicotinamide, 5 mg/mL yeast-extract and horse blood at 5% were added to CAeMH broth. A 0.005 mL portion of test organism solution, grown to turbidity of McFarland Number 0.5 and diluted tenfold with saline, was inoculated to CAeMH broth to make a final volume of 0.1 ± 0.02 mL. This was poured into a well on a microplate (Eiken Kagaku Co., Ltd., Tokyo, Japan) serially diluted freeze-dried test agent was placed, and the MIC was determined with the MIC2000 system (Eiken Kagaku Co., Ltd., Tokyo). Tested ranges were 0.06e128 mg/ml for CFDN, CDTR, CAM, and AZM, 0.06e32 mg/ml for TFLX, and 0.06e256 mg/ml for the other antimicrobials.
Detection of b-lactamases
To detect b-lactamases in H. influenzae, tests with Nitorocefin desks (Kanto Chemical Co, Inc., Tokyo) were conducted according to the reference manual supplied by the manufacturer.
A recently established rapid detection method, the CicaeBeta Test 1 ® (Kanto Chemical Co, Inc., Tokyo) being designed to detect Table 1 List of participating institution contributing to our surveillance.
extended spectrum b-lactamase (ESBL) and metallo b-lactamase (MBL) directly in colonies of Gram-negative rods [5] , was employed to identify K. pneumoniae and P. aeruginosa strains which produce such b-lactamases.
Results
Staphylococcus aureus
The in vitro antimicrobial susceptibilities, as MIC 50 ⁄ MIC 90 values, and the range of MICs for S. aureus isolates are shown in Table 2 . Among the total 206 strains of S. aureus, 104 strains (50.5%) were found to be methicillin-resistant S. aureus (MRSA; MIC of MPIPC ! 4 mg/mL) [ Table 3 ]. fluoroquinolones were within the range of 0.06e1.0 mg/mL. GRNX and STFX showed the strongest activities among the fluoroquinolones.
Susceptibility of MRSA
Only four agents, ABK, VCM, TEIC and LZD, showed strong activity against MRSA with MIC 90 of 2.0 mg/mL. MINO showed weak activity with MIC 90 s of 16 mg/mL. Other agents showed almost no activity, with MIC 90 s of !32 mg/mL.
Streptococcus pneumoniae
The susceptibilities of the 189 strains of S. pneumoniae to PCG revealed that 187 strains (98.9%), 2 strains (1.1%), and 0 strains (0.0%) were identified as penicillin-susceptible (PSSP), penicillinintermediate (PISP), and penicillin-resistant strains (PRSP), respectively, with the breakpoint for PCG defined by the CLSI standards [ Table 4 ].
Among the b-lactams, CCL, CAZ and CMZ showed high MIC 90 s (64, 8 and 16 mg/mL, respectively) while many of the other blactams, except for the carbapenems, showed potent activities, with MIC 90 s of 1.0e4.0 mg/mL. All five carbapenems showed strong activities (MIC 90 : 0.25 mg/mL) against all S. pneumoniae strains, regardless of their different susceptibilities to PCG. Fluoroquinolones also showed potent activities against the strains with MIC 90 s of 0.06e2 mg/mL. STFX was the strongest fluoroquinolone and the MIC against all strains was 0.5 mg/mL. The glycopeptides (VCM and TEIC) showed strong activities (MIC 90 : 0.5 mg/mL).
Aminoglycosides were substantially less active, with MIC 90 s of 8.0e64.0 mg/mL. High frequencies of resistance against the macrolide antibiotics, EM, CAM, and AZM, were shown, with MIC 90 s of !128 mg/mL.
Streptococcus pyogenes
The susceptibilities of the 4 S. pyogenes strains are summarized in Table 5 . All b-lactams showed strong activities (MIC 90 : 0.5 mg/ mL). Aminoglycosides and macrolides were less active, with MIC 90 s of 8.0e!256 mg/mL. Among fluoroquinolones, MFLX, GRNX and STFX showed potent activities (MIC 90 : 0.25 mg/mL), while the MIC 90 of PZFX was 4.0 mg/mL. 
Haemophilus influenzae
The susceptibilities of the 182 H. influenzae strains are summarized in Table 6 and Table 7 . According to the CLSI breakpoint for ABPC, 69 (37.9%) were found to be ABPC-susceptible, 32 (17.6%) to be ABPC-intermediate and 61 (33.5%) to be ABPC-resistant. With the use of the Nitrocephin disks, all ABPC-intermediate and ABPCresistant strains were found to be b-lactamase-non-producing, and they were defined as BLNAI and BLNAR, respectively. The other 20 (11.0%) ABPC-resistant strains were found to be b-lactamase-producing strains, designated as BLPAR. The MIC 50 and MIC 90 values of PCG and ABPC for BLPAR isolates were at least threefold higher than those for BLNAR isolates. However, there were no differences in the MIC 50 and MIC 90 values of SBT/ABPC and CVA/AMPC among BLNAR isolates and BLPAR isolates. Regardless of susceptibility to ABPC, all of the H. influenzae strains were extremely susceptible to all seven fluoroquinolones (MIC 50 s: 0.06 mg/mL). STFX showed a potent activity and the maximum MIC value was 0.25 mg/mL, whereas those of the other fluoroquinolones were 4.0-!32 mg/mL. BLPAR strains showed high levels of resistance against PIPC, with MIC 90 values of !256 mg/mL, whereas TAZ/PIPC showed strong activities, with MIC 90 s of 1.0 mg/mL. Among the cephems, CDTR, CAZ and CTRX showed the most potent activities, with MIC 90 s of 0.06 mg/ mL. Of the five carbapenem agents, MEPM showed the most potent activity against all types of H. influenzae strains. Among macrolide, AZM showed the most potent activity, with MIC 90 s of 2.0 mg/mL.
Moraxella catarrhalis
The susceptibilities of 74 M. catarrhalis strains are shown in AZM) also showed potent activities, with the MIC 90 s of 0.125e1.0 mg/mL.
Klebsiella pneumoniae
The susceptibilities of 139 K. pneumoniae strains are shown in Table 9 . Carbapenems showed strong activities, with MIC 90 s of 0.5 mg/mL; in particular, MEPM showed the most potent activities, with MIC 90 s 0.06 mg/mL. Of the cephems and the monobactam, CFPM showed the most potent activity, with MIC 90 s 0.06 mg/mL, respectively. Four of 139 strains (2.9%) were found to be ESBLproducing strains.
Pseudomonas aeruginosa
A total 160 P. aeruginosa strains were tested for antimicrobial susceptibility [ Table 10 ]. Among the b-lactams, three carbapenems (MEPM, BIPM and DRPM) showed potent activities, with MIC 50 s of 0.5 mg/mL; however, these agents showed relatively higher MIC 90 levels, of 8.0e16 mg/mL. Among the fluoroquinolones, STFX showed the most potent activity, with MIC 50 s and MIC 90 s of 0.25 and 4.0 mg/ mL, respectively. Other fluoroquinolones also showed strong activities with MIC 50 s of 0.25e2.0 mg/mL, whereas MIC 90 levels (8.0 to !32 mg/mL) suggested partial resistance. Both PIPC and TAZ/PIPC showed potent activities, with MIC 50 s of 8.0 mg/mL, but higher levels of MIC 90 s (128 mg/mL) of these agents were also observed.
The MIC 50 s of the four aminoglycosides (GM, TOB, AMK and ABK), three cephems (CAZ, CFPM and CZOP), and the monobactam (AZT)
were within the range of 1.0e8.0 mg/mL. Among the 160 P. aeruginosa isolates, we found 1 multidrug-resistant isolate (0.6%) and the isolate was confirmed to produce metallo-b-lactamase.
According to the CLSI breakpoint M100-S20, susceptible and resistant rates for PIPC were 87.5% and 12.5%, respectively. Proportions of susceptible/intermediate/resistant for carbapenems were 71.9/11.9/16.3 for IPM and 81.9/4.4/13.8 for MEPM.
Discussion
The Japanese Society of Chemotherapy (JSC) established a nationwide surveillance network in 2006 to establish the resource of information about antimicrobial susceptibility of bacterial pathogens in Japan. Our research focuses on major seven major bacterial respiratory pathogens, such as S. aureus, S. pneumoniae, S. pyogenes, H. influenzae, M. catarrhalis, K. pneumoniae and P. aeruginosa. It is desirable that analysis of antimicrobial susceptibility is done with the use of bacterial strains that actually cause the infections. To analyze the actual pathogens causing infections, we collected clinical isolates only from well-diagnosed adult patients with respiratory tract infections (RTIs).
Our surveillance was conducted for four consecutive years from 2006. The total number of strains at surveillance conducted in 2006, 2007, 2008, 2009 and 2010 were 887, 1108, 987, 635 and 955, respectively. To reflect the trend of pathogens of respiratory infections in Japan, we think we should increase the scope of the survey by reflecting results with a greater numbers of pathogens.
The ratio of MRSA was as high as 50.5% that was decreased from 58.5% in RTI 2009 [2] . These MRSA strains are susceptible to ABK, VCM, TEIC and LZD except that a few strains somewhat less susceptible (MIC 8.0 mg/mL) to TEIC. Although the emergence of resistant MRSA against VCM, TEIC or LZD has already been reported in Japan, such a resistant strain was not detected in this surveillance. The MRSA with a MIC of 2.0 mg/mL to VCM was 5.8% of MRSA. MRSA isolates with VCM MIC at 2.0 mg/mL are categorized in susceptible strains, however, the isolates can be associated with treatment failures, mainly in bloodstream infection [6] . Therefore, this population should be observed continuously in the next surveillance.
Since the surveillance in 2009 [2] , the susceptibility of S. pneumoniae to PCG was categorized with the new criteria of breakpoint MICs, and the proportion of PSSP/PISP/PRSP was found to be 99:1:0. These findings were similar to those in RTI 2009 (94:6:0) and suggest that penicillin is still effective against community-acquired pneumonia caused by S. pneumoniae but penicillin-intermediate strains are partly present. The susceptibility of 42 antimicrobial agents against 4 strains of S. pyogenes was determined.
To understand the trend of the susceptibility of S. pneumoniae to PCG, we also compared the ratio of the S. pneumoniae isolation in each year with the previous criteria, which was determined by reference to the susceptibility breakpoint for meningitis (0.06 mg/ Because it is difficult to detect these alarming trends by the new criteria of breakpoint MICs, careful watching using the previous criteria should be continuously needed.
Concerning H. influenzae, half of the strains in the present survey showed decreased susceptibility to ABPC without production of blactamase; BLNAI (17.6%) and BLNAR (33.5%). The ratio of BLNAI and BLNAR in adults is thought to be lower than in children [7] . The blactamase-producing clavulanic acid/ampicillin-resistant strains (BLPACR) have been also increasing and reached 4.8% of clinical isolates in children [7] . In this surveillance, we observed 7 (3.8%) BLPACR strains and the prevalence was similar to children, suggesting that BLPACR may be increasing in both children and adults. The prevalence of ESBL strains has become a concern in recent years. In 1990s, the ratio of ESBL among K. pneumoniae and E. coli was 0.3% and <0.1%, respectively [8] . The prevalence of this study (2.9%) was elevated when compared with the RTI 2009 (1.3%). The increasing tendency was also observed in previous reports [9, 10] .
The improvement of susceptibilities of b-lactams due to b-lactamase inhibitors might suggest that b-lactamase-producers including ESBL-producing strains.
In M100-S20 breakpoint criteria for K. pneumoniae [3] , no carbapenem-resistant isolate was observed. However, when based Table 6 Antibacterial susceptibility of Haemophilus influenzae (all strains and b-lactamase-producing strains).
Antimicrobial agent
All strains, n ¼ 182 The susceptibility of 40 antimicrobial agents against 182 strains of H. influenzae was determined. Table 7 Antibacterial susceptibility of b-lactamase-non-producing Haemophilus influenzae
Antimicrobial agent The susceptibility of 40 antimicrobial agents against 162 strains of b-lactamase-non-producing H. influenzae was determined.
on the updated criteria in M100-S21 [11] , one strain was considered to be intermediate for imipenem and resistant for meropenem. In the present survey, only one (0.6%) isolate of the 160 P. aeruginosa isolate was metallo-b-lactamase (MBL)-producing multidrug-resistant.
The proportion of MBL-producing P. aeruginosa was at a similar level to a previous report in which MBL-producing P. aeruginosa was detected at 1.6% [10] .
CLSI changed the break points of penicillins and carbapenems against P. aeruginosa in 2012 [12] . We also evaluated the resistant isolates according to the M100-S22 breakpoint criteria. Among penicillins, the intermediate range was newly categorized (32e64 mg/mL) and the susceptible strains for PIPC and TAZ/PIPC were shifted from 87.5% in M100-S20 to 79.4% and 80.0%, respectively. According to the M100-S22, proportions of susceptible/intermediate/resistant among P. aeruginosa were 67.5/4.4/28.1 for IPM and 76.9/5.0/18.1 for MEPM. Because the change of breakpoint criteria affects the proportions, the continuous evaluation will be also required in the next surveillance.
STFX was newly added in the present study. STFX showed stable activities to all species except for MRSA. However, we should keep appropriate use of antibiotics to prevent the emergence of resistant strain.
We think our surveillance data will be a useful reference for the treatment of respiratory infections in our country. There is The susceptibility of 40 antimicrobial agents against 74 strains of M. catarrhalis was determined. The susceptibility of 36 antimicrobial agents against 139 strains of K. pneumoniae was determined. The susceptibility of 35 antimicrobial agents against 160 strains of P. aeruginosa was determined.
substantial evidence that the overuse of antibiotics is a major cause for the emergence of resistance in respiratory pathogens. To prevent the further spread of antimicrobial resistance in respiratory pathogens, proper antibiotic use is needed. We should also continue the surveillance to determine the actual situation of the resistance shown by bacterial respiratory pathogens to antimicrobial agents.
